Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Top Cited Papers
- 1 March 2010
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 375 (9719) , 998-1006
- https://doi.org/10.1016/s0140-6736(10)60284-x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Nonalcoholic Fatty Liver Disease: Diagnostic and Fat-Grading Accuracy of Low-Flip-Angle Multiecho Gradient-Recalled-Echo MR Imaging at 1.5 TRadiology, 2009
- Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemiaNature Clinical Practice Cardiovascular Medicine, 2008
- Antisense, RNAi, and gene silencing strategies for therapy: Mission possible or impossible?Drug Discovery Today, 2008
- Hepatic MRI for Fat QuantitationJournal of Clinical Gastroenterology, 2005
- Long-term effects of LDL apheresis in patients with severe hypercholesterolemiaJournal of Clinical Apheresis, 2005
- An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosisJournal of Lipid Research, 2005
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Surgical Management of Dyslipidemia: Clinical and Experimental EvidenceJournal of Investigative Surgery, 2001